{"doc_id": "33234158", "type of study": "Therapy", "title": "", "abstract": "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.\nTo assess the efficacy of ivermectin in addition to standard treatment compared to standard treatment alone in reducing hospitalizations in the COVID-19 patient population.\nTRIAL DESIGN : IVERCOR-COVID19 will be a single-center, prospective, randomized, double-blind, parallel group (1:1 ratio), placebo-controlled study.\nPatients who meet the following criteria will be invited to participate: Inclusion criteria: (1) Over 18\u2009years of age who reside in the province of Corrientes at the time of diagnosis.\n(2) Confirmed diagnosis of COVID-19 by polymerase chain reaction (PCR) test for detection of SARS-CoV2 in the last 48\u2009h. (3) In the case of women of childbearing age, they must be using a contraceptive method of proven efficacy and safety (barrier, hormonal, or permanent contraceptives) for at least 3\u2009months prior to inclusion in the present study and for the entire period of time for the duration of the study and until at least 30\u2009days after the end of this study.\nA woman will be considered to have no reproductive capacity if she is postmenopausal (at least 2\u2009years without her menstrual cycles) or if she has undergone surgical sterilization (at least 1\u00a0month before the time of inviting her to participate in this study).\n(4) Weight at the time of inclusion greater than 48\u2009kg. (5) That they sign the informed consent for participation in the study.\nEXCLUSION CRITERIA : (1) pregnant or breastfeeding women; (2) known allergy to ivermectin or some of the components of ivermectin tablets or placebo; (3) current use of home oxygen; (4) require hospitalization due to COVID-19 at the time of diagnosis or history of hospitalization for COVID-19; (5) presence of mal-absorptive syndrome; (6) presence of any other concomitant acute infectious disease; (7) known history of severe liver disease, for example liver cirrhosis; (8) need or use of antiviral drugs at the time of admission for another viral pathology other than COVID-19; (9) need or use of hydroxychloroquine or chloroquine; (10) use of ivermectin up to 7\u2009days prior to randomization; (11) patients on dialysis or who have required it in the last 2\u2009months or who plan to do it in the next 2\u2009months; and (12) current participation or in the last 30\u2009days in a research study that has included the administration of a drug (Table\u00a01).\nTable 1 Ivermectin/placebo dose according to patient weight Patient weight Ivermectin/placebo dose Total dose (mg) Equal to or greater than 48\u00a0kg and less than 80\u00a0kg 2 tablets of 6\u2009mg each at the time of inclusion and 2 tablets 24\u2009h after the first intake 24 Equal or greater than 80\u00a0kg and less than 110\u00a0kg 3 tablets of 6\u2009mg each at the time of inclusion and 3 tablets 24\u2009h after the first intake 36 Equal or greater than 110\u00a0kg 4 tablets of 6\u2009mg each at the time of inclusion and 4 tablets 24\u2009h after the first intake 48 The study will be carried out by the Ministry of Public Health of the Province of Corrientes (Argentina) in coordination with the Institute of Cardiology of Corrientes in the Province of Corrientes, Argentina.\nINTERVENTION AND COMPARATOR : Intervention group: patients who are randomized to ivermectin will receive the dose according to their weight (patients up to 80\u2009kg will receive 2 tablets of 6\u2009mg ivermectin; patients with more than 80\u2009kg and up to 110\u2009kg will receive 3 tablets of 6\u2009mg of ivermectin; patients weighing more than 110\u2009kg will receive 4 tablets of 6\u2009mg ivermectin) the day they enter the study and the same dose 24\u2009h after the first dose.\nCONTROL GROUP : patients who are randomized to placebo will receive the dose according to their weight (patients up to 80\u2009kg will receive 2 tablets of 6\u2009mg placebo; patients with more than 80\u2009kg and up to 110\u2009kg will receive 3 tablets of 6\u2009mg of placebo; patients weighing more than 110\u2009kg will receive 4 tablets of 6\u2009mg placebo) on the day they enter the study and the same dose 24\u2009h after the first dose (Table 2).\nTable 2 Inclusion and exclusion criteria Inclusion criteria Exclusion criteria 1.\nOver 18\u2009years of age who reside in the province of Corrientes at the time of diagnosis 1.\nPregnant or breastfeeding women 2.Confirmed diagnosis of COVID-19 by polymerase chain reaction test for detection of SARS-CoV2 in the last 48\u2009h 2.\nKnown allergy to ivermectin or some of the components of ivermectin tablets or placebo 3.\nIn case of being women of childbearing age, they must be using a contraceptive method of proven efficacy and safety (barrier, hormonal, or permanent contraceptives) for at least 3\u2009months prior to inclusion in the present study, during the entire period of time for the duration of the study, and until at least 30\u2009days after the end of this study.\nA woman will be considered to have no reproductive capacity if she is postmenopausal (at least 2\u2009years without her menstrual cycles) or if she has undergone surgical sterilization (at least 1\u00a0month before the time of inviting her to participate in this study) 3.\nCurrent use of home oxygen 4.\nWeight at the time of inclusion equal to or greater than 48\u2009kg 4.\nThat require hospitalization due to COVID-19 at the time of diagnosis or history of hospitalization for COVID-19 5.\nThat they sign the informed consent for participation in the study 5.\nPresence of mal-absorptive syndrome 6.\nPresence of any other concomitant acute infectious disease 7.\nKnown history of severe liver disease, for example liver cirrhosis 8.\nNeed or use of antiviral drugs at the time of admission for another viral pathology other than COVID-19 9.\nNeed or use of hydroxychloroquine or chloroquine 10.\nUse of ivermectin up to 7\u2009days prior to randomization 11.\nPatients on dialysis or who have required it in the last 2\u2009months or who plan to do it in the next 2\u2009months 12.\nCurrent participation or in the last 30\u2009days in a research study that has included the administration of a drug MAIN OUTCOMES: Primary outcome will be the percentage of hospitalizations in patients with COVID-19 in the intervention and control groups.\nSECONDARY OUTCOMES : time to hospitalization in each of the arms of the study: number of days elapsed from the inclusion in the study until the hospitalization of the patient; percentage of use of invasive mechanical ventilation in each of the study arms: every patient who is connected to invasive mechanical ventilation after signing the informed consent and before the final study visit; time to invasive mechanical ventilation in each of the arms of the study: number of days elapsed from inclusion in the study to connection to invasive mechanical ventilation of the patient; percentage of patients requiring dialysis in each of the study arms: all patients who require renal replacement therapy of any kind, temporary or permanent, and which begins after signing the informed consent and before the final visit; mortality from all causes in each of the two trial groups: death of the patient, from any cause.\nNegative PCR swab at 3\u2009\u00b1\u20091 and 12\u2009\u00b1\u20092\u2009days after entering the study.\nIvermectin safety: it will be analyzed according to the incidence of adverse events that patients present in the intervention and control groups.\nThe end of study (EOS) is recorded as the day the patient is discharged or death.\nDischarge will be granted according to the current recommendations of the Ministry of Public Health of the Province of Corrientes.\nA follow-up visit (EOF) will be made by phone 30\u2009days after the EOS when vital status will be verified.\nRandomization will be done through a web system with randomly permuted blocks.\nRandomization will be carried out by one of the investigators who will not participate in the inclusion of patients or in the delivery of medication (Table 3).\nTable 3 EOS end of study, EOF end of follow-up Visit Basal and randomization, day 0 Day 3\u2009\u00b1\u20091 Day 12\u2009\u00b1\u20092 V#1 V#2 V#3 EOS EOF Informed consent X - - - - Inclusion/exclusion criteria X - - - - Demographic data and medical history X - - - - Concomitant medication X - - - - Vital signs* X X - - - Anthropometric data^ X - - - - Basal laboratory X - - - - PCR swab - X X - - Assessment of adverse events - X X X - Final objective evaluation - X X X X Randomization X - - - - Adherence to treatment X X - - - *Includes heart rate, temperature, and oxygen saturation by a digital saturometer ^Includes weight and height BLINDING\n(MASKING): The participants, investigators, care providers, and outcome assessors will be blinded.\nNUMBERS TO BE RANDOMIZED (SAMPLE SIZE)\n: We will include a total of 500 patients (250 patients in each group).\nTRIAL STATUS : This is version 1.0, 17 August 2020.\nThe recruitment started on 19 August 2020, and we anticipate the trial will finish recruitment on 31 December 2020.\nTRIAL REGISTRATION : ClinicalTrials.gov NCT04529525 .\nRegistered on 26 August 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).\nIn the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19 ( IVERCOR-COVID19 )", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 84}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 144, "end": 152}, {"term": "women", "negation": "affirmed", "UMLS": {}, "start": 147, "end": 152}, {"term": "childbearing age", "negation": "affirmed", "UMLS": {}, "start": 156, "end": 172}, {"term": "woman", "negation": "affirmed", "UMLS": {}, "start": 2, "end": 7}, {"term": "reproductive capacity", "negation": "negated", "UMLS": {}, "start": 38, "end": 59}, {"term": "postmenopausal", "negation": "negated", "UMLS": {}, "start": 70, "end": 84}, {"term": "surgical sterilization", "negation": "negated", "UMLS": {}, "start": 159, "end": 181}, {"term": "pregnant or breastfeeding women", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 58}, {"term": "known allergy to ivermectin or some of the components of ivermectin tablets or placebo", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 153}, {"term": "current use of home oxygen", "negation": "affirmed", "UMLS": {}, "start": 162, "end": 188}, {"term": "require hospitalization due to COVID-19", "negation": "affirmed", "UMLS": {}, "start": 197, "end": 236}, {"term": "presence of mal-absorptive syndrome", "negation": "affirmed", "UMLS": {}, "start": 313, "end": 348}, {"term": "presence of any other concomitant acute infectious disease", "negation": "affirmed", "UMLS": {}, "start": 357, "end": 415}, {"term": "history of severe liver disease", "negation": "affirmed", "UMLS": {}, "start": 430, "end": 461}, {"term": "liver cirrhosis", "negation": "affirmed", "UMLS": {}, "start": 476, "end": 491}, {"term": "need or use of antiviral drugs", "negation": "affirmed", "UMLS": {}, "start": 500, "end": 530}, {"term": "admission for another viral pathology other than COVID-19", "negation": "affirmed", "UMLS": {}, "start": 546, "end": 603}, {"term": "need or use", "negation": "negated", "UMLS": {}, "start": 500, "end": 511}, {"term": "dialysis", "negation": "negated", "UMLS": {}, "start": 745, "end": 753}, {"term": "than 80 kg", "negation": "affirmed", "UMLS": {}, "start": 227, "end": 237}, {"term": "110", "negation": "affirmed", "UMLS": {}, "start": 248, "end": 251}, {"term": "Pregnant or breastfeeding women", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 31}, {"term": "women", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 22}, {"term": "childbearing age", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 42}, {"term": "woman", "negation": "affirmed", "UMLS": {}, "start": 2, "end": 7}, {"term": "reproductive capacity", "negation": "negated", "UMLS": {}, "start": 38, "end": 59}, {"term": "postmenopausal", "negation": "negated", "UMLS": {}, "start": 70, "end": 84}, {"term": "surgical sterilization", "negation": "negated", "UMLS": {}, "start": 159, "end": 181}, {"term": "Presence of any other concomitant acute infectious disease", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 58}, {"term": "viral pathology other than", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 94}, {"term": "dialysis", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 20}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 204, "end": 212}, {"term": "renal replacement therapy of any kind", "negation": "affirmed", "UMLS": {}, "start": 682, "end": 719}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Ivermectin to prevent hospitalizations in patients with COVID-19 ( IVERCOR-COVID19 ) : a structured summary of a study protocol for a randomized controlled trial .", "Evidence Elements": {"Participant": [{"term": "COVID-19 ( IVERCOR-COVID19 )", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 84}], "Intervention": [{"term": "Ivermectin", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 10, "has_chemical": [{"text": "ivermectin", "maps_to": "C3537508:Privermectin", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [{"term": "hospitalizations", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 38}], "Observation": [{"term": "prevent", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 21}], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVES", "Text": "To assess the efficacy of ivermectin in addition to standard treatment compared to standard treatment alone in reducing hospitalizations in the COVID-19 patient population .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 144, "end": 152}], "Intervention": [{"term": "ivermectin in addition to standard treatment", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 70, "has_chemical": [{"text": "ivermectin", "maps_to": "C3537508:Privermectin", "start": 0, "end": 10}], "has_procedure": [{"text": "standard treatment", "maps_to": "C4684780:standard treatment", "start": 26, "end": 44}], "has_relation": "combined_with (C3537508<->C4684780)"}, {"term": "standard treatment alone", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 107, "has_procedure": [{"text": "standard treatment", "maps_to": "C4684780:standard treatment", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [{"term": "hospitalizations", "negation": "affirmed", "UMLS": {}, "start": 120, "end": 136}], "Observation": [{"term": "reducing", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 119}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL DESIGN : IVERCOR-COVID19 will be a single-center , prospective , randomized , double-blind , parallel group ( 1:1 ratio ) , placebo-controlled study .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "Patients who meet the following criteria will be invited to participate : Inclusion criteria : ( 1 ) Over 18 years of age who reside in the province of Corrientes at the time of diagnosis .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "( 2 ) Confirmed diagnosis of COVID-19 by polymerase chain reaction ( PCR ) test for detection of SARS-CoV2 in the last 48 h . ( 3 ) In the case of women of childbearing age , they must be using a contraceptive method of proven efficacy and safety ( barrier , hormonal , or permanent contraceptives ) for at least 3 months prior to inclusion in the present study and for the entire period of time for the duration of the study and until at least 30 days after the end of this study .", "Evidence Elements": {"Participant": [{"term": "women", "negation": "affirmed", "UMLS": {}, "start": 147, "end": 152}, {"term": "childbearing age", "negation": "affirmed", "UMLS": {}, "start": 156, "end": 172}], "Intervention": [], "Outcome": [{"term": "of SARS-CoV2", "negation": "affirmed", "UMLS": {}, "start": 94, "end": 106}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "A woman will be considered to have no reproductive capacity if she is postmenopausal ( at least 2 years without her menstrual cycles ) or if she has undergone surgical sterilization ( at least 1 month before the time of inviting her to participate in this study ) .", "Evidence Elements": {"Participant": [{"term": "woman", "negation": "affirmed", "UMLS": {}, "start": 2, "end": 7}, {"term": "reproductive capacity", "negation": "negated", "UMLS": {}, "start": 38, "end": 59}, {"term": "postmenopausal", "negation": "negated", "UMLS": {}, "start": 70, "end": 84}, {"term": "surgical sterilization", "negation": "negated", "UMLS": {}, "start": 159, "end": 181}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "( 4 ) Weight at the time of inclusion greater than 48 kg . ( 5 ) That they sign the informed consent for participation in the study .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "EXCLUSION CRITERIA : ( 1 ) pregnant or breastfeeding women ; ( 2 ) known allergy to ivermectin or some of the components of ivermectin tablets or placebo ; ( 3 ) current use of home oxygen ; ( 4 ) require hospitalization due to COVID-19 at the time of diagnosis or history of hospitalization for COVID-19 ; ( 5 ) presence of mal-absorptive syndrome ; ( 6 ) presence of any other concomitant acute infectious disease ; ( 7 ) known history of severe liver disease , for example liver cirrhosis ; ( 8 ) need or use of antiviral drugs at the time of admission for another viral pathology other than COVID-19 ; ( 9 ) need or use of hydroxychloroquine or chloroquine ; ( 10 ) use of ivermectin up to 7 days prior to randomization ; ( 11 ) patients on dialysis or who have required it in the last 2 months or who plan to do it in the next 2 months ; and ( 12 ) current participation or in the last 30 days in a research study that has included the administration of a drug ( Table 1 ) .", "Evidence Elements": {"Participant": [{"term": "pregnant or breastfeeding women", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 58}, {"term": "known allergy to ivermectin or some of the components of ivermectin tablets or placebo", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 153}, {"term": "current use of home oxygen", "negation": "affirmed", "UMLS": {}, "start": 162, "end": 188}, {"term": "require hospitalization due to COVID-19", "negation": "affirmed", "UMLS": {}, "start": 197, "end": 236}, {"term": "presence of mal-absorptive syndrome", "negation": "affirmed", "UMLS": {}, "start": 313, "end": 348}, {"term": "presence of any other concomitant acute infectious disease", "negation": "affirmed", "UMLS": {}, "start": 357, "end": 415}, {"term": "history of severe liver disease", "negation": "affirmed", "UMLS": {}, "start": 430, "end": 461}, {"term": "liver cirrhosis", "negation": "affirmed", "UMLS": {}, "start": 476, "end": 491}, {"term": "need or use of antiviral drugs", "negation": "affirmed", "UMLS": {}, "start": 500, "end": 530}, {"term": "admission for another viral pathology other than COVID-19", "negation": "affirmed", "UMLS": {}, "start": 546, "end": 603}, {"term": "need or use", "negation": "negated", "UMLS": {}, "start": 500, "end": 511}, {"term": "dialysis", "negation": "negated", "UMLS": {}, "start": 745, "end": 753}], "Intervention": [{"term": "hydroxychloroquine", "negation": "negated", "UMLS": {}, "start": 627, "end": 645, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "chloroquine", "negation": "negated", "UMLS": {}, "start": 634, "end": 645, "has_chemical": [{"text": "chloroquine", "maps_to": "C0055461:dichloroquine", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "ivermectin", "negation": "negated", "UMLS": {}, "start": 84, "end": 94, "has_chemical": [{"text": "ivermectin", "maps_to": "C3537508:Privermectin", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Table 1 Ivermectin / placebo dose according to patient weight Patient weight Ivermectin / placebo dose Total dose ( mg ) Equal to or greater than 48 kg and less than 80 kg 2 tablets of 6 mg each at the time of inclusion and 2 tablets 24 h after the first intake 24 Equal or greater than 80 kg and less than 110 kg 3 tablets of 6 mg each at the time of inclusion and 3 tablets 24 h after the first intake 36 Equal or greater than 110 kg 4 tablets of 6 mg each at the time of inclusion and 4 tablets 24 h after the first intake 48 The study will be carried out by the Ministry of Public Health of the Province of Corrientes ( Argentina ) in coordination with the Institute of Cardiology of Corrientes in the Province of Corrientes , Argentina .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo dose", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 33, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "placebo dose Total dose ( mg )", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 120, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "Equal to or greater than 48 kg and less than 80 kg 2 tablets of 6 mg", "negation": "affirmed", "UMLS": {}, "start": 121, "end": 189, "has_relation": "N/A"}, {"term": "Equal or greater than 80 kg and less than 110 kg 3 tablets of 6 mg", "negation": "affirmed", "UMLS": {}, "start": 265, "end": 331, "has_relation": "N/A"}, {"term": "Equal or greater than 110 kg 4 tablets of 6 mg", "negation": "affirmed", "UMLS": {}, "start": 407, "end": 453, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "INTERVENTION AND COMPARATOR : Intervention group : patients who are randomized to ivermectin will receive the dose according to their weight ( patients up to 80 kg will receive 2 tablets of 6 mg ivermectin ; patients with more than 80 kg and up to 110 kg will receive 3 tablets of 6 mg of ivermectin ; patients weighing more than 110 kg will receive 4 tablets of 6 mg ivermectin ) the day they enter the study and the same dose 24 h after the first dose .", "Evidence Elements": {"Participant": [{"term": "than 80 kg", "negation": "affirmed", "UMLS": {}, "start": 227, "end": 237}, {"term": "110", "negation": "affirmed", "UMLS": {}, "start": 248, "end": 251}], "Intervention": [{"term": "ivermectin", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 92, "has_chemical": [{"text": "ivermectin", "maps_to": "C3537508:Privermectin", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "dose according to their weight", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 140, "has_procedure": [{"text": "their weight", "maps_to": "C1305866:weight", "start": 18, "end": 30}], "has_activity": [{"text": "according", "maps_to": "C0680240:according", "start": 5, "end": 14}], "has_relation": "N/A"}, {"term": "2 tablets of 6 mg ivermectin", "negation": "affirmed", "UMLS": {}, "start": 177, "end": 205, "has_chemical": [{"text": "ivermectin", "maps_to": "C3537508:Privermectin", "start": 18, "end": 28, "has_strength": ["6 mg"], "has_form": ["tablets"], "has_dosage": ["2"]}], "has_relation": "N/A"}, {"term": "3 tablets of 6 mg of ivermectin", "negation": "affirmed", "UMLS": {}, "start": 268, "end": 299, "has_chemical": [{"text": "ivermectin", "maps_to": "C3537508:Privermectin", "start": 21, "end": 31, "has_form": ["tablets"], "has_strength": ["6 mg"], "has_dosage": ["3"]}], "has_relation": "N/A"}, {"term": "4 tablets of 6 mg ivermectin", "negation": "affirmed", "UMLS": {}, "start": 350, "end": 378, "has_chemical": [{"text": "ivermectin", "maps_to": "C3537508:Privermectin", "start": 18, "end": 28, "has_strength": ["6 mg"], "has_form": ["tablets"], "has_dosage": ["4"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "CONTROL GROUP : patients who are randomized to placebo will receive the dose according to their weight ( patients up to 80 kg will receive 2 tablets of 6 mg placebo ; patients with more than 80 kg and up to 110 kg will receive 3 tablets of 6 mg of placebo ; patients weighing more than 110 kg will receive 4 tablets of 6 mg placebo ) on the day they enter the study and the same dose 24 h after the first dose ( Table 2 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 54, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "2 tablets of 6 mg placebo", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 164, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 18, "end": 25, "has_strength": ["6 mg"], "has_form": ["tablets"], "has_dosage": ["2"]}], "has_relation": "N/A"}, {"term": "3 tablets of 6 mg of placebo", "negation": "affirmed", "UMLS": {}, "start": 227, "end": 255, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 21, "end": 28, "has_form": ["tablets"], "has_strength": ["6 mg"], "has_dosage": ["3"]}], "has_relation": "N/A"}, {"term": "4 tablets of 6 mg placebo", "negation": "affirmed", "UMLS": {}, "start": 306, "end": 331, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 18, "end": 25, "has_strength": ["6 mg"], "has_form": ["tablets"], "has_dosage": ["4"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Table 2 Inclusion and exclusion criteria Inclusion criteria Exclusion criteria 1 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Over 18 years of age who reside in the province of Corrientes at the time of diagnosis 1 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Pregnant or breastfeeding women 2 . Confirmed diagnosis of COVID-19 by polymerase chain reaction test for detection of SARS-CoV2 in the last 48 h 2 .", "Evidence Elements": {"Participant": [{"term": "Pregnant or breastfeeding women", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 31}], "Intervention": [], "Outcome": [{"term": "Confirmed diagnosis of COVID-19", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 67}, {"term": "detection of SARS-CoV2", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 128}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Known allergy to ivermectin or some of the components of ivermectin tablets or placebo 3 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "In case of being women of childbearing age , they must be using a contraceptive method of proven efficacy and safety ( barrier , hormonal , or permanent contraceptives ) for at least 3 months prior to inclusion in the present study , during the entire period of time for the duration of the study , and until at least 30 days after the end of this study .", "Evidence Elements": {"Participant": [{"term": "women", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 22}, {"term": "childbearing age", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 42}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "A woman will be considered to have no reproductive capacity if she is postmenopausal ( at least 2 years without her menstrual cycles ) or if she has undergone surgical sterilization ( at least 1 month before the time of inviting her to participate in this study ) 3 .", "Evidence Elements": {"Participant": [{"term": "woman", "negation": "affirmed", "UMLS": {}, "start": 2, "end": 7}, {"term": "reproductive capacity", "negation": "negated", "UMLS": {}, "start": 38, "end": 59}, {"term": "postmenopausal", "negation": "negated", "UMLS": {}, "start": 70, "end": 84}, {"term": "surgical sterilization", "negation": "negated", "UMLS": {}, "start": 159, "end": 181}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Current use of home oxygen 4 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Weight at the time of inclusion equal to or greater than 48 kg 4 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "That require hospitalization due to COVID-19 at the time of diagnosis or history of hospitalization for COVID-19 5 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "That they sign the informed consent for participation in the study 5 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Presence of mal-absorptive syndrome 6 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Presence of mal-absorptive syndrome", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 35}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Presence of any other concomitant acute infectious disease 7 .", "Evidence Elements": {"Participant": [{"term": "Presence of any other concomitant acute infectious disease", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 58}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Known history of severe liver disease , for example liver cirrhosis 8 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Need or use of antiviral drugs at the time of admission for another viral pathology other than COVID-19 9 .", "Evidence Elements": {"Participant": [{"term": "viral pathology other than", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 94}], "Intervention": [], "Outcome": [{"term": "or use", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 11}, {"term": "drugs", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 30}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Need or use of hydroxychloroquine or chloroquine 10 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 33, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "chloroquine", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 33, "has_chemical": [{"text": "chloroquine", "maps_to": "C0055461:dichloroquine", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Use of ivermectin up to 7 days prior to randomization 11 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "ivermectin", "negation": "affirmed", "UMLS": {}, "start": 7, "end": 17, "has_chemical": [{"text": "ivermectin", "maps_to": "C3537508:Privermectin", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Patients on dialysis or who have required it in the last 2 months or who plan to do it in the next 2 months 12 .", "Evidence Elements": {"Participant": [{"term": "dialysis", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 20}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Current participation or in the last 30 days in a research study that has included the administration of a drug MAIN OUTCOMES : Primary outcome will be the percentage of hospitalizations in patients with COVID-19 in the intervention and control groups .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 204, "end": 212}], "Intervention": [{"term": "intervention", "negation": "affirmed", "UMLS": {}, "start": 220, "end": 232, "has_procedure": [{"text": "intervention", "maps_to": "C0886296:intervention", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 237, "end": 244, "has_relation": "N/A"}], "Outcome": [{"term": "percentage of hospitalizations", "negation": "affirmed", "UMLS": {}, "start": 156, "end": 186}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "SECONDARY OUTCOMES : time to hospitalization in each of the arms of the study : number of days elapsed from the inclusion in the study until the hospitalization of the patient ; percentage of use of invasive mechanical ventilation in each of the study arms : every patient who is connected to invasive mechanical ventilation after signing the informed consent and before the final study visit ; time to invasive mechanical ventilation in each of the arms of the study : number of days elapsed from inclusion in the study to connection to invasive mechanical ventilation of the patient ; percentage of patients requiring dialysis in each of the study arms : all patients who require renal replacement therapy of any kind , temporary or permanent , and which begins after signing the informed consent and before the final visit ; mortality from all causes in each of the two trial groups : death of the patient , from any cause .", "Evidence Elements": {"Participant": [{"term": "renal replacement therapy of any kind", "negation": "affirmed", "UMLS": {}, "start": 682, "end": 719}], "Intervention": [{"term": "each of the arms", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 64, "has_relation": "N/A"}, {"term": "each of the study", "negation": "affirmed", "UMLS": {}, "start": 234, "end": 251, "has_procedure": [{"text": "study", "maps_to": "C0947630:study", "start": 12, "end": 17}], "has_relation": "N/A"}, {"term": "each of the arms", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 64, "has_relation": "N/A"}, {"term": "each of the study", "negation": "affirmed", "UMLS": {}, "start": 234, "end": 251, "has_procedure": [{"text": "study", "maps_to": "C0947630:study", "start": 12, "end": 17}], "has_relation": "N/A"}, {"term": "each of the", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 59, "has_relation": "N/A"}], "Outcome": [{"term": "time to hospitalization", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 44}, {"term": "number of days elapsed from the inclusion in the study until the hospitalization of the patient", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 175}, {"term": "percentage of use of invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 178, "end": 230}, {"term": "connected to invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 280, "end": 324}, {"term": "time to invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 395, "end": 434}, {"term": "number of days elapsed from inclusion in the study to connection to invasive mechanical ventilation of the patient", "negation": "affirmed", "UMLS": {}, "start": 470, "end": 584}, {"term": "percentage of patients requiring dialysis", "negation": "affirmed", "UMLS": {}, "start": 587, "end": 628}, {"term": "or", "negation": "affirmed", "UMLS": {}, "start": 346, "end": 348}, {"term": "mortality from all causes", "negation": "affirmed", "UMLS": {}, "start": 828, "end": 853}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Negative PCR swab at 3 \u00b11 and 12 \u00b12 days after entering the study .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Negative PCR swab", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 17}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Ivermectin safety : it will be analyzed according to the incidence of adverse events that patients present in the intervention and control groups .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "intervention", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 126, "has_procedure": [{"text": "intervention", "maps_to": "C0886296:intervention", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 131, "end": 138, "has_relation": "N/A"}], "Outcome": [{"term": "Ivermectin safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 17}, {"term": "incidence of adverse events", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 84}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The end of study ( EOS ) is recorded as the day the patient is discharged or death .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "end of study ( EOS )", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 24}, {"term": "patient is discharged", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 73}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Discharge will be granted according to the current recommendations of the Ministry of Public Health of the Province of Corrientes .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "A follow-up visit ( EOF ) will be made by phone 30 days after the EOS when vital status will be verified .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RANDOMIZATION", "Text": "Randomization will be done through a web system with randomly permuted blocks .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RANDOMIZATION", "Text": "Randomization will be carried out by one of the investigators who will not participate in the inclusion of patients or in the delivery of medication ( Table 3 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RANDOMIZATION", "Text": "Table 3 EOS end of study , EOF end of follow-up Visit Basal and randomization , day 0 Day 3 \u00b1 1 Day 12 \u00b1 2 V # 1 V # 2 V # 3 EOS EOF Informed consent X ---- Inclusion / exclusion criteria X---- Demographic data and medical history X---- Concomitant medication X---- Vital signs * X X--- Anthropometric data ^ X---- Basal laboratory X ---- PCR swab-X X-- Assessment of adverse events -X X X- Final objective evaluation -X X X X Randomization X ---- Adherence to treatment X X ---* Includes heart rate , temperature , and oxygen saturation by a digital saturometer ^ Includes weight and height BLINDING", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "medication", "negation": "affirmed", "UMLS": {}, "start": 249, "end": 259}, {"term": "Vital signs", "negation": "affirmed", "UMLS": {}, "start": 266, "end": 277}, {"term": "Anthropometric data", "negation": "affirmed", "UMLS": {}, "start": 287, "end": 306}, {"term": "PCR swab-X", "negation": "affirmed", "UMLS": {}, "start": 339, "end": 349}, {"term": "adverse events", "negation": "affirmed", "UMLS": {}, "start": 368, "end": 382}, {"term": "objective evaluation", "negation": "affirmed", "UMLS": {}, "start": 397, "end": 417}, {"term": "Adherence to treatment", "negation": "affirmed", "UMLS": {}, "start": 448, "end": 470}, {"term": "heart rate", "negation": "affirmed", "UMLS": {}, "start": 489, "end": 499}, {"term": "temperature", "negation": "affirmed", "UMLS": {}, "start": 502, "end": 513}, {"term": "oxygen saturation", "negation": "affirmed", "UMLS": {}, "start": 520, "end": 537}, {"term": "weight", "negation": "affirmed", "UMLS": {}, "start": 574, "end": 580}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RANDOMIZATION", "Text": "( MASKING ) : The participants , investigators , care providers , and outcome assessors will be blinded .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "NUMBERS TO BE RANDOMIZED ( SAMPLE SIZE )", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": ": We will include a total of 500 patients ( 250 patients in each group ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL STATUS : This is version 1.0 , 17 August 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The recruitment started on 19 August 2020 , and we anticipate the trial will finish recruitment on 31 December 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : ClinicalTrials.gov NCT04529525 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Registered on 26 August 2020 FULL PROTOCOL : The full protocol is attached as an additional file , accessible from the Trials website ( Additional file 1 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "In the interest of expediting the dissemination of this material , the familiar formatting has been eliminated ; this letter serves as a summary of the key elements of the full protocol .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}